<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01188759</url>
  </required_header>
  <id_info>
    <org_study_id>A1501095</org_study_id>
    <nct_id>NCT01188759</nct_id>
  </id_info>
  <brief_title>Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects</brief_title>
  <official_title>A Prospective, Randomized Trial Comparing The Safety, Tolerability, And Efficacy Of Voriconazole And Anidulafungin In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Invasive Aspergillosis in Pediatric Subjects Aged 2 to 17 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the safety, tolerability, and efficacy of voriconazole and
      anidulafungin in combination versus voriconazole alone in pediatric subjects aged 2 to 17
      years with invasive aspergillosis.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of voriconazole and anidulafungin in combination versus voriconazole alone as determined by rates of adverse events</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of all-cause mortality at 6 weeks</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of all-cause mortality at EOT</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global response to therapy at 6 weeks</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global response to therapy at EOT</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Aspergillosis</condition>
  <condition>Invasive Pulmonary Aspergillosis</condition>
  <condition>Neuroaspergillosis</condition>
  <arm_group>
    <arm_group_label>Voriconazole and Anidulafungin Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the combination arm will receive voriconazole and anidulafungin in combination for 2-4 weeks followed by voriconazole monotherapy to complete 6-12 weeks of therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Voriconazole Monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in the monotherapy arm will receive voriconazole monotherapy for 6-12 weeks of therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole</intervention_name>
    <description>For Children aged 2-11 years and adolescents aged 12-14 years weighing &lt;50 kg:
Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.
For adolescents aged 12-17 years, excluding 12-14-year-olds weighing &lt;50kg:
Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.
Voriconazole therapy is to be given for 6-12 weeks.</description>
    <arm_group_label>Voriconazole and Anidulafungin Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anidulafungin</intervention_name>
    <description>Anidulafungin 3 mg/kg IV load q24h x 24h (maximum 200 mg), then 1.5 mg/kg q24h (maximum 100 mg).
Anidulafungin therapy is to be given for 2-4 weeks in combination with voriconazole.</description>
    <arm_group_label>Voriconazole and Anidulafungin Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole</intervention_name>
    <description>For Children aged 2-11 years and adolescents aged 12-14 years weighing &lt;50 kg:
Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.
For adolescents aged 12-17 years, excluding 12-14-year-olds weighing &lt;50kg:
Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.
Voriconazole therapy is to be given for 6-12 weeks.</description>
    <arm_group_label>Voriconazole Monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of proven, probable, or possible invasive aspergillosis.

          -  Hematologic malignancy or allogeneic hematopoetic stem cell transplant.

        Exclusion Criteria:

          -  Sarcoidosis, aspergilloma, or allergic bronchopulmonary aspergillosis.

          -  Chronic invasive aspergillosis.

          -  Receipt of antifungal treatment for more than 96 hours.

          -  Severe liver dysfunction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>Egypt</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1501095&amp;StudyName=Voriconazole%20And%20Anidulafungin%20Combination%20For%20Invasive%20Aspergillosis%20In%20Pediatric%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2010</study_first_submitted>
  <study_first_submitted_qc>August 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2010</study_first_posted>
  <last_update_submitted>May 10, 2012</last_update_submitted>
  <last_update_submitted_qc>May 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aspergillosis</keyword>
  <keyword>Combination Therapy</keyword>
  <keyword>Voriconazole</keyword>
  <keyword>Anidulafungin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
    <mesh_term>Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Invasive Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Neuroaspergillosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
    <mesh_term>Anidulafungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

